Brought to you by 
Merck, Pfizer partner with Dako to create companion diagnostic for avelumab
06 Oct 2021
Executive Summary
Expanding upon an existing agreement, Merck KGAA and Pfizer Inc. have enlisted the help of Agilent Technologies' Dako AS to develop a companion diagnostic for avelumab (MSB0010718C).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Pfizer partner with Dako to create companion diagnostic for avelumab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice